A decision support tool to reduce overtestingfor ceruloplasmin and improve adherence with clinical guidelines

JAMA Internal Medicine

Volumn 175, Issue 9, 2015, Pages 1561-1562

  Tapper, Elliot B ^a   Sengupta, Neil ^a   Lai, Michelle ^a   Horowitz, Gary ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CERULOPLASMIN; COPPER;

BLOOD ANALYSIS; CERULOPLASMIN BLOOD LEVEL; DECISION SUPPORT SYSTEM; HEALTH CARE UTILIZATION; HUMAN; LABORATORY DIAGNOSIS; LETTER; LIVER DISEASE; LIVER LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; URINALYSIS; VIRUS HEPATITIS; WILSON DISEASE; AGED; CLINICAL TRIAL; HEALTH SERVICE; HEPATOLENTICULAR DEGENERATION; MIDDLE AGED; PREVENTION AND CONTROL; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CERULOPLASMIN; DECISION SUPPORT SYSTEMS, CLINICAL; GUIDELINE ADHERENCE; HEPATOLENTICULAR DEGENERATION; HUMANS; MEDICAL OVERUSE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84941247860     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.2062     Document Type: Letter

References (5)

1. Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA. 2012;307(17):1801-1802.
2. Tapper EB, Patwardhan VR, Curry M. Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency [published online December 23, 2014]. Dig Dis Sci. 2014;1-6.
3. Tapper EB, Rahni DO, Arnaout R, Lai M. The overuse of serum ceruloplasmin measurement. Am J Med. 2013;126(10):926.e1-926.e5.
4. Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089-2111.
5. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967.